Phenytoin intoxication induced by fluvoxamine

Therapeutic Drug Monitoring

Volumn 23, Issue 1, 2001, Pages 75-77

  Mamiya, Kohsuke ^a   Kojima, Kyoji ^b   Yukawa, Eiji ^c   Higuchi, Shun ^c   Ieiri, Ichiro ^d   Ninomiya, Hideaki ^b   Tashiro, Nobutada ^b  

^a Hizen National Hospital   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

Author keywords

CYP2C subfamily; Drug interaction; Fluvoxamine; Intoxication; Phenytoin

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; FLUVOXAMINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ALLELE; ARTICLE; ATAXIA; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG METABOLISM; DRUG WITHDRAWAL; EPILEPSY; FEMALE; GENOTYPE; HUMAN; PRIORITY JOURNAL;

ALLELES; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; ATAXIA; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; FLUVOXAMINE; GENOTYPE; HUMANS; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENYTOIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0035135648     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200102000-00014     Document Type: Article

References (21)

1. Depression in epilepsy: Etiology, phenomenology, and treatment
2. Drugs and the treatment of psychiatric disorders
3. Citalopram: Interaction with levomepromazine, imipramine, and lithium
4. Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P450 2D6 inhibition in vivo
5. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers
6. Fluvoxamine and fluoxetine: Interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients
7. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide
8. Mexiletine metabolism in vitro by human liver
9. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxylation
10. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide
11. Toxic reaction following the combined administration of fluoxetine and phenytoin: Two case reports
12. Interaction between phenytoin and fluoxetine
13. Interaction of phenytoin and fluoxetine
14. Fluoxetine inhibition of phenytoin metabolism
15. Elevated serum phenytoin concentrations associated with coadministration of sertraline
16. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult epileptic patients; studies in stereoselective hydroxylation and population pharmacokinetics
17. Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine, and Ameltolide (LY201116)
18. Inhibition of alprazolam metabolism in vitro: Effect of serotonin reuptake inhibitor antidepressants, ketoconazole and quinidine
19. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical conformation of a predicted interaction with ketoconazole
20. Selective serotonin reuptake inhibitors and theophyline metabolism in human liver microsomes: Potent inhibition by fluvoxamine
21. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2